Boston Scientific Corporation $BSX Stake Decreased by Baader Bank Aktiengesellschaft

Baader Bank Aktiengesellschaft trimmed its holdings in Boston Scientific Corporation (NYSE:BSX) by 20.6% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 8,189 shares of the medical equipment provider’s stock after selling 2,127 shares during the quarter. Baader Bank Aktiengesellschaft’s holdings in Boston Scientific were worth $830,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in BSX. Investment Management Corp VA ADV bought a new position in shares of Boston Scientific in the fourth quarter worth $25,000. Sunbeam Capital Management LLC bought a new stake in shares of Boston Scientific during the 4th quarter worth about $26,000. 1248 Management LLC acquired a new stake in shares of Boston Scientific in the 1st quarter worth approximately $26,000. Y.D. More Investments Ltd bought a new position in shares of Boston Scientific in the first quarter valued at approximately $27,000. Finally, Ameriflex Group Inc. bought a new stake in Boston Scientific during the fourth quarter worth approximately $31,000. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

BSX stock opened at $98.29 on Friday. Boston Scientific Corporation has a one year low of $80.64 and a one year high of $109.50. The firm has a 50-day moving average of $104.51 and a two-hundred day moving average of $102.15. The firm has a market capitalization of $145.64 billion, a PE ratio of 58.51, a P/E/G ratio of 2.37 and a beta of 0.65. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. The business had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm’s quarterly revenue was up 22.8% compared to the same quarter last year. During the same period last year, the firm posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Oppenheimer raised Boston Scientific from a “market perform” rating to an “outperform” rating and increased their price target for the company from $118.00 to $125.00 in a research note on Monday, September 8th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Boston Scientific in a research note on Thursday, July 24th. Raymond James Financial boosted their price target on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 24th. Jefferies Financial Group restated a “hold” rating on shares of Boston Scientific in a research report on Monday, July 21st. Finally, Robert W. Baird boosted their target price on shares of Boston Scientific from $117.00 to $123.00 and gave the stock an “outperform” rating in a report on Thursday, July 24th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $118.04.

Insider Activity

In other news, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the sale, the director owned 2,081 shares in the company, valued at $222,646.19. This represents a 58.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,469,268. This represents a 42.32% decrease in their position. The disclosure for this sale can be found here. Insiders sold 174,214 shares of company stock valued at $18,397,457 in the last 90 days. Company insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.